Processes for making, and methods of using, glycopyrronium compounds

ABSTRACT

Provided herein are processes for making and methods of using salts of glycopyrronium, including solid forms and forms suitable for use as topicals. Disclosed here are processes for making salts of glycopyrronium, also processes for making compositions comprising salts of glycopyrronium, and methods of treating hyperhidrosis with salts of glycopyrronium as well as with compositions comprising salts of glycopyrronium such as, but not limited to, topical compositions. Disclosed herein are methods of treating hyperhidrosis including administering salts of glycopyrronium to subjects in need thereof.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Patent ApplicationNo. 62/370,172, filed Aug. 2, 2016, the entire content of which isherein incorporated by reference in its entirety for all purposes.

FIELD

The present disclosure sets forth synthetic processes and chemicalreagents for making glycopyrronium salts, stereospecifically andstereoselectively, including particular stereoisomers and mixtures ofstereoisomers in high yield and with high selectivity. Also set forthherein are derivatives and analogs of glycopyrronium salts.

BACKGROUND

Certain glycopyrronium salts and related compounds, as well as processesfor making and methods of using these glycopyrronium salts and relatedcompounds, are known. See, for example, U.S. Pat. No. 8,558,008, whichissued to assignee Dermira, Inc. See also, for example, U.S. Pat. No.2,956,062, which issued to assignee Robins Co Inc. A H. See also, forexample, International Patent Application Publication Nos. WO 98/00132A1 and WO 2009/00109A1, both of which list applicant Sepracor, Inc., aswell as U.S. Pat. Nos. 6,063,808 and 6,204,285, both of which issued toassignee Sepracor, Inc. Certain methods of treating hyperhidrosis usingglycopyrronium salts and related compounds are known. See, for exampleGB 1,080,960. Certain forms of applying glycopyrrolate compounds to asubject are known. See, for example U.S. Pat. Nos. 6,433,003 and8,618,160, both of which issued to assignee Rose U; also U.S. Pat. Nos.7,060,289; 8,252,316; and 8,679,524, which issued to PurePharm, Inc.

One glycopyrronium salt which is useful in certain medical applicationsis the following compound:

As illustrated above, the absolute configuration at the three asymmetricchiral positions is 2R3′R1′RS. This means that the carbon indicated withthe number, 2, has the stereochemical R configuration. The carbonindicated with the number, 3′, also has the stereochemical Rconfiguration. The quaternary ammonium nitrogen atom, indicated with apositive charge, may have either the R or the S stereochemicalconfiguration. As drawn, the compound above is a mixture of twodiastereoisomers.

Certain processes for making glycopyrronium salts are known. However,these processes are not as safe, efficient, stereospecific, orstereoselective as the new processes disclosed herein, for example withrespect to large-scale manufacturing processes. Certain publicationsshow that higher anticholinergic activity is attributed to the 2R3′Rconfiguration. However, to date, processes for making the 2R3′R isomers,as well as the 2R3′R1′R isomers are low yielding, involve too manyreaction steps to be economically feasible, use toxic materials, and/orare not sufficiently stereospecific or stereoselective with respect tothe products formed.

SUMMARY

In one embodiment, set forth herein is a process for making a compoundof Formula (I):

wherein:

-   -   R¹ and R² are each, independently in each instance, selected        from alkyl and alkyl substituted with alkoxycarbonyl;    -   the stereochemical configuration about the carbon atom indicated        by 2 is R;    -   the stereochemical configuration about carbon atom indicated by        3′ is R;    -   X⁻ is an anion;        wherein the process includes step (1) contacting a compound of        Formula (Ia) with a compound of Formula (Ib) under coupling        conditions to form a compound of Formula (Ic):

and step (2) contacting a compound of Formula (Ic) with a compound ofFormula (Id) to make a compound of Formula (I):

In a second embodiment, set forth herein is a process for making acompound of Formula (Ib):

In some embodiments, R¹ is selected from alkyl and alkyl substitutedwith alkoxycarbonyl.In some embodiments, the process includes step (1): providing a compound(5):

In some embodiments, the process includes step (2): contacting compound(5) with an alkyl-amine (e.g., R¹—NH₂) to form a compound of Formula(Ibc):

In some embodiments, the process includes contacting compound of Formula(Ibc) with reducing agent (indicated by [H⁺], below) to form a compoundof Formula (Ib):

In a third embodiment, set forth herein is a composition including amixture of compounds having following structures (Ia1) and (Ia2):

In some embodiments, the compounds having structures (Ia1) and (Ia2) areprepared by a process disclosed herein. In some embodiments, thecompounds are formulated with a pharmaceutically acceptable excipient,diluent, or salt. R¹ R², and X⁻ are as defined above for Formula (I).

In a fourth embodiment, set forth herein is a process for treatinghyperhidrosis, including administering to a subject in need thereof acomposition comprising a compound prepared by a process disclosed hereinor a composition disclosed herein.

In a fifth embodiment, set forth herein is a method of treating adisease or disorder marked by a need for an anticholinergic agent,including administering to a subject in need thereof a compositioncomprising a compound prepared by a process disclosed herein or acomposition disclosed herein.

BRIEF DESCRIPTIONS OF THE DRAWINGS

FIG. 1 shows an example synthesis for making a glycopyrronium salt.

FIG. 2 shows an example synthesis for making a glycopyrronium salt.

FIG. 3 shows an example synthesis for making a glycopyrronium salt.

FIG. 4 shows an example synthesis for making a glycopyrronium salt.

DETAILED DESCRIPTION

Set forth herein are processes for making compounds having twostereocenters with the stereochemical R configuration. For example, setforth herein are processes for making glycopyrronium salts, includingbut not limited to, coupling cyclopentylmandelic acid (CPMA) (or anester derivative thereof) to 1-methyl-3-hydroxypyrrolidine (NMHP)followed by alkylation at the 1′-position of the resultingglycopyrronium base (GPB), using an alkylating agent, such as, but notlimited to, ethyl bromoacetate. In some examples, set forth herein is anefficient process for coupling 2-(R)-CPMA with 3-(R)-NMHP to make a2R3′R-GPB directly, followed by alkylation at the N1′ position.

A. DEFINITIONS

As used herein, the term “yield,” refers to the empirical yield for agiven chemical reaction. Yield is a percent which represents the extentto which a reaction proceeded to produce a given product. Percent yieldis calculated by assuming a chemical reaction and assuming that all ofthe chemical reagents react and become products, limited only by thelimiting reagent wherein the limiting reagent is the reagent which isconsumed first as the reaction proceeds. This initial calculationproduces what is known as the theoretical yield. Once the reaction isempirically performed, the products are analyzed. The amounts ofproducts may be massed, determined spectroscopically, or determined byother empirical means. The amount of products massed, determinedspectroscopically, or determined by other empirical means represents theempirical yield. “Yield” as used herein and in the claims refers to thequotient of the empirical yield over the theoretical yield, and thenmultiplied by 100. For example, in the reaction A+2B→C, if one has 1mole of A and 1 mole of B, then B is the limiting reagent since 2 molesof B are needed to react with 1 mole of A. According to the reactionexample, 1 mole of B will produce 0.5 moles of C. If 1 mole of A reactswith 1 mole of B, and one determines empirically that 0.4 moles of Cwere produced, then the theoretical yield would be 0.5 moles, and theempirical yield would be 0.4 moles. The percent yield would be thereforebe 80% since (0.4/0.5)(100)=80%.

As used herein, the term “alkyl” refers to a monovalent and saturatedhydrocarbon radical moiety. Alkyl is optionally substituted and can belinear, branched, or cyclic, i.e., cycloalkyl. Alkyl includes, but isnot limited to, those having 1-20 carbon atoms, i.e., C₁₋₂₀ alkyl; 1-12carbon atoms, i.e., C₁₋₁₂ alkyl; 1-8 carbon atoms, i.e., C₁₋₈ alkyl; 1-6carbon atoms, i.e., C₁₋₆ alkyl; and 1-3 carbon atoms, i.e., C₁₋₃ alkyl.Examples of alkyl moieties include, but are not limited to methyl,ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, butyl, a pentylmoiety, a hexyl moiety, cyclopropyl, cyclobutyl, cyclopentyl, andcyclohexyl.

As used herein, the term “cycloalkyl” refers to a cyclic alkyl.Cycloalkyl is optionally substituted. Examples of cycloalkyl moietiesinclude, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl,cyclohexyl, cycloheptyl, and cyclooctyl.

As used herein, “alkoxy” refers to a monovalent and saturatedhydrocarbon radical moiety wherein the hydrocarbon includes a singlebond to an oxygen atom and wherein the radical is localized on theoxygen atom, e.g. CH₃CH₂—O. for ethoxy. Alkoxy substituents bond to thecompound which they substitute through this oxygen atom of the alkoxysubstituent. Alkoxy is optionally substituted and can be linear,branched, or cyclic, i.e., cycloalkoxy. Alkoxy includes, but is notlimited to, those having 1-20 carbon atoms, i.e., C₁₋₂₀ alkoxy; 1-12carbon atoms, i.e., C₁₋₁₂ alkoxy; 1-8 carbon atoms, i.e., C₁₋₈ alkoxy;1-6 carbon atoms, i.e., C₁₋₆ alkoxy; and 1-3 carbon atoms, i.e., C₁₋₃alkoxy. Examples of alkoxy moieties include, but are not limited tomethoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy,i-butoxy, a pentoxy moiety, a hexoxy moiety, cyclopropoxy, cyclobutoxy,cyclopentoxy, and cyclohexoxy.

As used herein, the term “alkoxycarbonyl,” refers to a monovalent andsaturated hydrocarbon radical moiety wherein the hydrocarbon includes asingle carbon bond to an oxygen atom, which is further bonded to acarbonyl, e.g., C(O). The oxygen atom is a bivalent atomic linkerbetween the alkyl portion of the alkoxycarbonyl and the carbonyl. Theradical in alkoxycarbonyl is localized on the carbon atom of thecarbonyl which is bonded to an oxygen atom of an alkoxy e.g.CH₃CH₂—O—C.(O). Alkoxycarbonyl substituents bond to the compound whichthey substitute through this carbonyl carbon atom. Alkoxycarbonyl isoptionally substituted and can be linear or branched. Alkoxycarbonylincludes, but is not limited to, those having 1-20 carbon atoms, i.e.,C₁₋₂₀ alkoxycarbonyl; 1-12 carbon atoms, i.e., C₁₋₁₂ alkoxycarbonyl; 1-8carbon atoms, i.e., C₁₋₈ alkoxycarbonyl; 1-6 carbon atoms, i.e., C₁₋₆alkoxycarbonyl; and 1-3 carbon atoms, i.e., C₁₋₃ alkoxycarbonyl.Examples of alkoxy moieties include, but are not limited tomethoxycarbonyl, and ethoxycarbonyl.

As used herein, the term “halo” refers to a halogen substituent. Halogensubstituents include fluoro, chloro, bromo, and iodo.

As used herein, the phrase “using a salt-resolution procedure,” refersto a process for using a salt, e.g., 5-nitroisophthalate salt, toisolate or purify one stereoisomer from a mixture of stereoisomers,e.g., mixtures of diastereomers. Exemplary processes for using asalt-resolution procedure are set forth in Finnish Patent 49713, whichissued Sep. 10, 1975 and which was filed May 15, 1974.

As used herein, the phrase “coupling conditions,” refers to reactionconditions and reactions which are suitable to bond two compoundstogether, or which catalyze the bonding of two compounds together. Forexample, U.S. Pat. No. 9,006,462, which issued to Dermira, Inc., setsforth example coupling conditions which include reagents such as but notlimited to 1,1-carbonyldiimidazole in toluene.

As used herein, the phrase “stereomerically pure,” refers to aparticular stereoisomer of a compound which is present to a greaterextent than other stereoisomers of that compound, e.g., the compound ispresent in diastereomeric excess or the compound is present inenantiomeric excess. In some embodiments, the stereomerically purecompounds described herein include 80% or greater, 85% or greater, 90%or greater, 95% or greater, or 97% or greater by weight of onestereoisomer of the compound. In some embodiments, the stereomericallypure compounds described herein include 80% or greater, 85% or greater,90% or greater, 95% or greater, or 97% or greater by mole of onestereoisomer of the compound.

As used herein, the term “anion,” refers to a negatively charged atom ormolecule, e.g., a halide or a tosylate. Herein, anion includes a specieswhich charge balances the positively charged species to which the anionis associated or paired. For example, some salts provided herein includea positively charged quaternary ammonium group. This positively chargedquaternary ammonium group forms a neutrally charged salt by bondingionically to an anion(s), such as but not limited to, fluoride,chloride, bromide, iodide, benzoate, edisylate, oxalate, hydrogensulfate, and tosylate.

B. PROCESS FOR MAKING GLYCOPYRRONIUM SALTS

In certain examples, set forth here is a process for making a compoundof Formula (I):

-   In Formula (I), R¹ and R² are each, independently in each instance,    selected from alkyl and alkyl substituted with alkoxycarbonyl;    the stereochemical configuration about the carbon atom indicated by    2 is R;    the stereochemical configuration about carbon atom indicated by 3′    is R; and    X⁻ is an anion.

In some of these examples, R¹ is alkyl. In other examples, R¹ is methyl,ethyl, n-propyl, i-propyl, n-butyl, t-butyl, i-butyl, n-pentyl, ori-pentyl. In some examples, R¹ is methyl or ethyl. In some otherexamples, R¹ is methyl. In other examples, R¹ is ethyl.

In some examples, R² is alkyl. In some examples, R² is methyl, ethyl,n-propyl, i-propyl, n-butyl, t-butyl, i-butyl, n-pentyl, or i-pentyl. Incertain examples, R² is methyl or ethyl. In some examples, R² is methyl.In other examples, R² is ethyl. In some examples, both R¹ and R² aremethyl.

In some of these examples, R¹ is alkyl. In some examples, R¹ is methyl,ethyl, n-propyl, i-propyl, n-butyl, t-butyl, i-butyl, n-pentyl, ori-pentyl. In certain examples, R¹ is methyl or ethyl. In some examples,R¹ is methyl. In other examples, R¹ is ethyl. In any of these examplesin this paragraph, R² is alkyl. In some examples, R² is methyl, ethyl,n-propyl, i-propyl, n-butyl, t-butyl, i-butyl, n-pentyl, or i-pentyl. Incertain examples, R² is methyl or ethyl. In some examples, R² is methyl.In other examples, R² is ethyl. In some examples, both R¹ and R² aremethyl.

In some of the examples herein, R¹ is alkyl substituted withalkoxycarbonyl. In some examples, R¹ is methyl substituted withalkoxycarbonyl. In some examples, R¹ is —CH₂C(O)OCH₂CH₃. In some of theexamples in this paragraph, R² is alkyl. In certain examples, R² ismethyl or ethyl. In some examples, R² is methyl. In other examples, R²is ethyl.

In certain examples, the processes for making a compound of Formula (I)include step (1): contacting a compound of Formula (Ia) with a compoundof Formula (Ib) under coupling conditions to form a compound of Formula(Ic):

In some examples, compound (Ia) is treated with one equivalent ofcarbonyldiimideazole (CDI) in toluene at ambient temperature and allowedto react under agitation for 1-2 hours to form an activated form ofcompound (Ia). In some examples, approximately one equivalent ofcompound (Ib) is added to the activated form of compound (Ia). Incertain examples, the reaction mixture is further warmed to about 70° C.In some examples, the reaction mixture is further agitated. In someexamples, the agitation is maintained until the reaction is complete asmeasured by monitoring the disappearance or consumption of compound (Ib)or of the activated form of compound (Ia). In some examples, thereaction is complete in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 hours.In some examples, the reaction is complete within 6-8 hours. In someexamples, the processes herein further include washing thetoluene-including solution 3-4 times with purified water to remove theimidazole side product. In some examples, the processes further includeconcentrating the organic phase under vacuum to leave an oil which maybe used directly in other processes disclosed herein.

In some examples of the processes for making a compound of Formula (Ic),the reaction is carried out in one or more solvents. The solvent(s) canbe any solvent deemed suitable to those of skill in the art for carryingout the reaction. In certain embodiments, the solvent(s) does notappreciably react with the compound of Formula (Ia) or (Ib). In certainembodiments, the solvent(s) is selected from toluene.

In some examples, the solvent is selected from the group consisting ofethers, esters, aromatics, alkanes, chlorinated solvents and ketones. Insome examples, the solvent is selected from the group consisting ofN-methyl-pyrrolidone (NMP), dimethyl formamide (DMF) anddimethylacetamide (DMAC). In some examples, when the solvent is anether, the solvent is selected from tetrahydrofuran (THF), methyltetrahydrofuran (MeTHF), methyl tert-butyl ethyl (MTBE), andcombinations thereof. In some examples, when the solvent is an ester,the solvent is selected from ethyl acetate, isopropyl acetate, andcombinations thereof. In some examples, when the solvent is an aromatic,the solvent is selected from toluene, chlorobenzene, xylenes, andcombinations thereof. In some examples, when the solvent is an alkane,the solvent is selected from pentane, hexane, heptane, and combinationsthereof. In some examples, when the solvent is a chlorinated solvent,the solvent is selected from dichloromethane, chloroform, andcombinations thereof. In some examples, when the solvent is a ketone,the solvent is selected from methyl ethyl ketone (MEK). In someexamples, the solvent in a combination of any of the aforementionedsolvents. In some examples, the solvent is a combination of any of theabove ethers, esters, aromatics, alkanes, chlorinated solvents andketone solvents. In some examples, the solvent is selected from NMP,DMF, DMAC, THF, MeTHF, MTBE, ethyl acetate, isopropyl acetate, toluene,chlorobenzene, xylenes, pentane, hexane, heptane, dichloromethane,chloroform, methyl ethyl ketone, and combinations thereof. In someexamples, the solvent includes NMP, DMF, DMAC, THF, MeTHF, MTBE, ethylacetate, isopropyl acetate, toluene, chlorobenzene, xylenes, pentane,hexane, heptane, dichloromethane, chloroform, methyl ethyl ketone, orcombinations thereof.

In some examples, the concentration of the compound according to Formula(Ia) or (Ib) is about 0.1M to about 2 M. In some examples, theconcentration of the compound according to Formula (Ia) or (Ib) is about0.1M, 0.2M, 0.3M, 0.4M, 0.5M, 0.6M, 0.7M, 0.8M. 0.9M or 1M. In someexamples, the concentration of the compound according to Formula (Ia) or(Ib) is about 0.5M.

In some examples, the processes herein include using an excess of thecompound of Formula (Ia) with respect to compound (Ib). In someexamples, the processes herein include using about 5% by mole excess ofthe compound (Ia) with respect to compound (Ib). In some examples, thereaction includes about three times (i.e., 3×) by mole excess of thealkylating agent compound (Ia) with respect to compound (Ib).

The processes for making a compound of Formula (Ic) are carried out atany temperature deemed suitable by those of skill in the art. Inparticular embodiments, the reaction is conducted at any temperaturefrom about 0° C. to about 80° C., from about 10° C. to about 75° C.,from about 20° C. to about 65° C., or from about 30° C. to about 55° C.In particular embodiments, the reaction is at room temperature. Inparticular embodiments, the reaction is at about 20° C., about 21° C.,about 22° C., about 23° C., about 24° C., about 25° C., about 26° C.,about 27° C., about 28° C., about 29° C., about 30° C., about 31° C.,about 32° C., about 33° C., about 34° C., about 35° C., about 36° C.,about 37° C., about 38° C., about 39° C., about 40° C., about 41° C.,about 42° C., about 43° C., about 44° C., about 45° C., about 46° C.,about 47° C., about 48° C., about 49° C., about 50° C., about 51° C.,about 52° C., about 53° C., about 54° C., about 55° C., about 56° C.,about 57° C., about 58° C., about 59° C., about 60° C., about 61° C.,about 62° C., about 63° C., about 64° C., about 65° C., about 66° C.,about 67° C., about 68° C., about 69° C., about 70° C., about 71° C.,about 72° C., about 73° C., about 74° C., about 75° C., about 76° C.,about 77° C., about 78° C., about 79° C., about 80° C., about 81° C.,about 82° C., about 83° C., about 84° C., or about 85° C.

The processes for making a compound of Formula (Ic) are carried out inany volume deemed suitable by those of skill in the art and depends onthe size of the reaction. In particular embodiments, the reaction volumeis at least about 50 mL, at least about 100 mL, at least about 150 mL,at least about 200 mL, at least about 225 mL, at least about 250 mL, atleast about 500 mL, at least about 1 L, at least about 2 L, at leastabout 3 L, at least about 4 L, or at least about 5 L. In anotherembodiment, the reaction volume is at least about 200 mL to at leastabout 10,000 L. In another embodiment, the reaction volume is at leastabout 1000 L, at least about 5000 L, or at least about 10,000 L.

The reaction above can proceed for any time deemed suitable forformation of compound (Ic). In particular embodiments, the reactionproceeds for about 1 hour, about 2 hours, about 3 hours, about 4 hours,about 5 hours, or about 6 hours. In particular embodiments, the reactionproceeds for about 1 to about 6 hours, in another embodiment about 1 toabout 4 hours, in another embodiment about 2 to about 4 hours, inanother embodiment about 2.5 to about 3.5 hours. Reaction progress canbe monitored by standard techniques such as thin layer chromatography orhigh-performance liquid chromatography. In certain embodiments, thereaction proceeds in about 6 to about 8 hours. In certain embodiments,the reaction proceeds in about 6 to about 8 hours at 70° C.

In some examples, the reaction progress is monitored by observing theconsumption of compounds of Formula (Ia) or (Ib) by either thin-layerchromatograph (TLC) or high-pressure liquid chromatography (HPLC).

In some examples, the processes for making a compound of Formula (I)further include step (2): contacting a compound of Formula (Ic) with acompound of Formula (Id) under coupling conditions to make a compound ofFormula (I):

In certain examples the processes for making a compound of Formula (I)further includes using an appropriate solvent at room temperature and a3-fold excess of compound of Formula (Id) with respect to the compoundof Formula (Ic). In some examples, the product compound of Formula (I)may crystallize from the reaction mixture. In some of those examples,wherein the compound of Formula (I) does crystallize, it may berecovered by filtration. In some of the examples herein, the crudeproduct is purified by trituration or recrystallization from anappropriate solvent.

In some examples of the processes for contacting a compound of Formula(Ic) with a compound of Formula (Id) under coupling conditions to make acompound of Formula (I), the reaction is carried out in one or moresolvents. The solvent(s) can be any solvent deemed suitable to those ofskill in the art for carrying out the reaction. In certain embodiments,the solvent(s) does not appreciably react with the compound of Formula(Ic) or (Id). In certain embodiments, the solvent(s) is selected fromacetonitrile. In some examples, the concentration of the compoundaccording to Formula (Ic) or (Id) is about 0.1M to about 2 M. In someexamples, the concentration of the compound according to Formula (Ic) or(Id) is about 0.1M, 0.2M, 0.3M, 0.4M, 0.5M, 0.6M, 0.7M, 0.8M, 0.9M or1M. In some examples, the concentration of the compound according toFormula (Ic) or (Id) is about 0.5M. The compound according to Formula(Id) is used in an amount of at least about 1 equivalents with respectto the compound of Formula (Ic), and in some embodiments about compound(Id) is in at least a 5% molar excess compared to the compound ofFormula (Ic). In some embodiments compound (Id) is in at least a 5%molar excess compared to the compound of Formula (Ic). In some examples,compound (Id) is present in 5-15 volumetric portions with respect tocompound (Ic). In some examples, the concentration of the compoundaccording to Formula (Id) is present at a concentration of about 0.1M,0.2M, 0.3M, 0.4M, 0.5M, 0.6M, 0.7M, 0.8M. 0.9M or 1M. In some examples,the concentration of the compound according to Formula (Ic) is about0.1M, 0.2M, 0.3M, 0.4M, 0.5M, 0.6M, 0.7M, 0.8M. 0.9M or 1M. In someexamples, the concentration of the compound according to Formula (Id) isabout 0.3M-1M. In some examples, the concentration of the compoundaccording to Formula (Ic) is about 0.3M-1M.

The processes for contacting a compound of Formula (Ic) with a compoundof Formula (Id) under coupling conditions to make a compound of Formula(I) are carried out at any temperature deemed suitable by those of skillin the art. In particular embodiments, the reaction is conducted at anytemperature from about 0° C. to about 80° C., from about 10° C. to about75° C., from about 20° C. to about 65° C., or from about 30° C. to about55° C. In particular embodiments, the reaction is at room temperature.In particular embodiments, the reaction is at about 20° C., about 21°C., about 22° C., about 23° C., about 24° C., about 25° C., about 26°C., about 27° C., about 28° C., about 29° C., about 30° C., about 31°C., about 32° C., about 33° C., about 34° C., about 35° C., about 36°C., about 37° C., about 38° C., about 39° C., about 40° C., about 41°C., about 42° C., about 43° C., about 44° C., about 45° C., about 46°C., about 47° C., about 48° C., about 49° C., about 50° C., about 51°C., about 52° C., about 53° C., about 54° C., about 55° C., about 56°C., about 57° C., about 58° C., about 59° C., about 60° C., about 61°C., about 62° C., about 63° C., about 64° C., about 65° C., about 66°C., about 67° C., about 68° C., about 69° C., about 70° C., about 71°C., about 72° C., about 73° C., about 74° C., about 75° C., about 76°C., about 77° C., about 78° C., about 79° C., about 80° C., about 81°C., about 82° C., about 83° C., about 84° C., or about 85° C.

In some examples, the aforementioned reaction is carried out at roomtemperature. In some examples, this reaction is run at a temperaturehigher than room temperature, for example, when bulky substituents arepresent on the reactant compounds.

The processes for contacting a compound of Formula (Ic) with a compoundof Formula (Id) under coupling conditions to make a compound of Formula(I) are carried out in any volume deemed suitable by those of skill inthe art and depends on the size of the reaction. In particularembodiments, the reaction volume is at least about 50 mL, at least about100 mL, at least about 150 mL, at least about 200 mL, at least about 225mL, at least about 250 mL, at least about 500 mL, at least about 1 L, atleast about 2 L, at least about 3 L, at least about 4 L, or at leastabout 5 L. In another embodiment, the reaction volume is at least about200 mL to at least about 10,000 L. In another embodiment, the reactionvolume is at least about 1000 L, at least about 5000 L, or at leastabout 10,000 L.

The reaction above can proceed for any time deemed suitable forformation of compound (I). In particular embodiments, the reactionproceeds for about 1 hour, about 2 hours, about 3 hours, about 4 hours,about 5 hours, or about 6 hours. In particular embodiments, the reactionproceeds for about 1 to about 6 hours, in another embodiment about 1 toabout 4 hours, in another embodiment about 2 to about 4 hours, inanother embodiment about 2.5 to about 3.5 hours. Reaction progress canbe monitored by standard techniques such as thin layer chromatography orhigh-performance liquid chromatography, In some examples, the reactiontime will depend on the substituents present on the compound of Formula(Id). In some examples, the reaction time will depend on the reactiontemperature. In some examples, the reaction time will depend on themolar excess of compound (Id) with respect to compound (Ic). In certainexamples, the reaction is complete at room temperature in about 3 hourswhen compound (Id) is ethyl bromoacetate.

Also described herein are processes for monitoring the reactionprogress, including, but not limited to, monitoring the residual amountof compound (Id) or (Ic) by thin layer chromatography (TLC), gaschromatography (GC) by high-pressure liquid chromatograph (HPLC). Insome examples, the monitoring the reaction progress is by TLC. In someexamples, the monitoring the reaction progress is by GC. In someexamples, the monitoring the reaction progress is by HPLC.

In certain examples, the processes for making a compound of Formula (I)further include step (3): isolating a stereomerically pure stereoisomerof a compound of Formula (I). In some examples, the stereomerically purestereoisomer of a compound of Formula (I) is present in an enantiomericexcess of at least 80%. In some examples, the stereomerically purestereoisomer of a compound of Formula (I) is present in an enantiomericexcess of at least 85%. In some examples, the stereomerically purestereoisomer of a compound of Formula (I) is present in an enantiomericexcess of at least 90%. In some examples, the stereomerically purestereoisomer of a compound of Formula (I) is present in an enantiomericexcess of at least 95%. In some examples, the stereomerically purestereoisomer of a compound of Formula (I) is present in an enantiomericexcess of at least 99%. In some examples, the stereomerically purestereoisomer of a compound of Formula (I) is present in andiastereomeric excess of at least 80%. In some examples, thestereomerically pure stereoisomer of a compound of Formula (I) ispresent in an diastereomeric excess of at least 85%. In some examples,the stereomerically pure stereoisomer of a compound of Formula (I) ispresent in an diastereomeric excess of at least 90%. In some examples,the stereomerically pure stereoisomer of a compound of Formula (I) ispresent in an diastereomeric excess of at least 95%. In some examples,the stereomerically pure stereoisomer of a compound of Formula (I) ispresent in an diastereomeric excess of at least 99%.

In some examples, the processes for making a compound of Formula (I)further include isolating a compound of Formula (I) by columnchromatography. In some of these examples, the isolating of a compoundof Formula (I) is by column chromatography. In some examples, theprocesses for making a compound of Formula (I) further include isolatinga compound of Formula (I) using the relative solubility of the5-nitroisophthalate salt of a compound of Formula (I). For example, insome examples, the processes for making a compound of Formula (I)include making the 2R3′R1′ of a compound of Formula (I). For example, insome examples, the processes for making a compound of Formula (I)include making the 2R3′S1′ of a compound of Formula (I). Based on thisdifference in solubility, the threo pair can be separated from theerythro pair, e.g., by precipitating the low solubility pair and washingaway the higher solubility pair.

In certain examples, the processes for making a compound of Formula (I)include, prior to contacting a compound of Formula (Ic) with a compoundof Formula (Id) to make a compound of Formula (I), isolating astereoisomer of a compound of Formula (Ic) from a mixture ofstereoisomers of compounds of Formula (Ic). In these examples, themixture of mixture of stereoisomers of compounds of Formula (Ic) may beprovided by a commercial source or generated in-situ.

In some examples, step (1) of the process for making a compound ofFormula (I) includes contacting a compound of Formula (Ia) with acompound of Formula (Ib) under coupling conditions to form a compound ofFormula (Ic) as follows:

In some of these examples, R¹ is alkyl. In other examples, R¹ is methyl,ethyl, n-propyl, i-propyl, n-butyl, t-butyl, i-butyl, n-pentyl, ori-pentyl. In some examples, R¹ is methyl or ethyl. In some otherexamples, R¹ is methyl. In other examples, R¹ is ethyl.

In certain examples, the processes for making a compound of Formula (I)include, in step (1) contacting a compound of Formula (Ia-1) with acompound of Formula (Ib-1) under coupling conditions to form a compoundof Formula (Ic-1) as follows:

In some examples, the processes for making a compound of Formula (I)include, in step (1), providing stereomerically pure compounds ofFormula (Ia) and Formula (Ib).

In any of the examples of the processes for making a compound of Formula(I) include, the compound of Formula (I) can include the followingstructures (Ia1) or (Ia2):

In some examples, the compound of Formula (Ia1) is present in a greaterconcentration than is a compound of Formula (Ia2).

In some other examples, the compound of Formula (Ia2) is present in agreater concentration than is a compound of Formula (Ia1).

In some examples, the compound of Formula (I) comprises a mixture ofcompounds having the following structures:

In some examples, R¹ and R² are selected so that the pyrrolidinylnitrogen atom has (S) stereochemistry about its nitrogen atom. In someof these examples, the compound of Formula (I) is the following:

In some examples, R¹ and R² are selected so that the pyrrolidinylnitrogen atom has (R) stereochemistry about its nitrogen atom. In someexamples, the compound of Formula (I) is the following:

In some examples of the processes for making a compound of Formula (I),in step (1) a compound of Formula (Ib-s) is present in addition to acompound of Formula (Ib):

In some examples, the processes for making a compound of Formula (I)result in a yield of a compound of Formula (I) is at least 30%. In someexamples, the yield is at least 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%,75%, 80%, 85%, 90%, or 95%.

In some examples, the processes for making a compound of Formula (I)include isolating compound (Ic) from a mixture of compound (Ic) and itsstereoisomers using chiral resolution agents and salts. In someexamples, the processes include using various salts, various acids, orcombinations thereof, to separate stereoisomers, e.g., diastereoisomers.In certain examples, the acid is a nitroisophthalic acid.

In some examples, the isolating step includes the isolating processesset forth in Finnish Patent Application No. 1495/75 which issued Sep.10, 1975 as Finnish Patent 49713. Finnish Patent Application No. 1495/75and Finnish Patent 49713 sets forth processes for makingerythro-1-methyl-3-pyrrolidinyl-alpha-cyclopentylmandelate methylbromide. For example, generally, a mixture of compound (Ic) and itsstereoisomers can be converted to nitroisophthalic acid saltderivatives. Each isomer salt derivative can then be crystallized. Eachisomer salt has a different solubility. By using the difference insolubilities of these salts, these nitroisophthalic acid saltderivatives of a mixture of compound (Ic) and its stereoisomers can eachbe separated from each other. Once separated from each other, thenitrophthalic acid salt moiety can be removed from the nitrophthalicsalt derivative compound using an inorganic base. As set forth inFinnish Patent Application No. 1495/75 and Finnish Patent 49713, theerythro (RR/SS) and threo (RS/SR) enantiomeric pairs of compound (Ic)can be separated from each other by a nitroisophthalate salt process.The technique relies on the lower solubility of the 5-nitroisophthalatesalt of the threo pair as compared to the erythro pair. As set forth inFinnish Patent Application No. 1495/75 or Finnish Patent 49713, thethreo salts crystallize preferentially leaving the salt of the erythropair in solution. By separating the solution from the solid crystal, theerythro (RR/SS) and threo (RS/SR) enantiomeric pairs of compound Mc(e.g., IIIc-1) can be separated. The stereoisomer resolution techniquesfrom Finnish Patent Application No. 1495/75 or from Finnish Patent 49713are herein incorporated by reference in their entirety for all purposes.

In any of the above processes, R¹ can include alkyl. In any of the aboveprocesses, R¹ can include methyl, ethyl, n-propyl, i-propyl, n-butyl,t-butyl, i-butyl, n-pentyl, or i-pentyl. In any of the above processes,R¹ can include methyl or ethyl. In any of the above processes, R¹ caninclude methyl. In any of the above processes, R¹ can include ethyl.

In any of the above processes, X can be a halide. For example, X caninclude F⁻, Cl⁻, Br⁻, I⁻ or combinations thereof. In some examples, X isBr⁻.

In any of the above processes, R² can include alkyl. In any of the aboveprocesses, R² can include methyl, ethyl, n-propyl, i-propyl, n-butyl,t-butyl, i-butyl, n-pentyl, or i-pentyl. In any of the above processes,R² can include methyl or ethyl. In any of the above processes, R¹ caninclude methyl. In any of the above processes, R² can include ethyl.

In any of the above processes, R¹ can include alkyl substituted withalkoxycarbonyl and R² as alkyl.

In any of the above processes, R¹ can include alkyl substituted withalkoxycarbonyl and R² as methyl.

In any of the above processes, R¹ can include —CH₂C(O)OCH₂CH₃ and R² asalkyl.

In any of the above processes, R¹ can include R¹—CH₂C(O)OCH₂CH₃ and R²as methyl. In some examples, R¹ is —CH₂C(O)OCH₂CH₃ and R² is methyl.

In some examples herein, the compound of Formula (Ia) is compound (4):

In some examples herein, the compound of Formula (Ib) is compound (7):

In some examples herein, the compound of Formula (Ic) is compound (8):

In some examples herein, the compound of Formula (I) is the followingcompound:

In some examples herein, the compound of Formula (I) is compound (9):

In some examples herein, the compound of Formula (Id) is the followingcompound:

In some examples herein, the compound of Formula (Id) is compound (10):

In some examples herein, the compound of Formula (Ia) is compound (4):

In some examples, compound (4) is made by contacting compound (3):

with a methanolic base. In some examples, compound (4) is made bycontacting compound (3):

with a base in methanol. In some examples, this methanolic base isselected from methanolic alkali or alkaline earth hydroxide bases. Incertain examples, the methanolic base is KOH in methanol. In someexamples, this methanolic base is selected from an alkali or alkalineearth hydroxide base in methanol.

In some examples herein, the compound of Formula (Ia) is compound (4):

In some examples, compound (4) is made by contacting compound (3):

with methanolic potassium hydroxide.

In some of these examples the contacting of compound (3) with methanolicpotassium hydroxide is at about 65° C. In some of these examples thecontacting of compound (3) with methanolic potassium hydroxide is atabout 50° C. to about 80° C. In some of these examples the contacting ofcompound (3) with methanolic potassium hydroxide is at about 50° C. Insome of these examples the contacting of compound (3) with methanolicpotassium hydroxide is at about 55° C. In some of these examples thecontacting of compound (3) with methanolic potassium hydroxide is atabout 60° C. In some of these examples the contacting of compound (3)with methanolic potassium hydroxide is at about 65° C. In some examples,the processes further include cooling compound (4). In some examples,the processes further include removing the methanol from the methanolicpotassium hydroxide. In some examples, the processes further includeadding an acid and extracting compound (4) with an organic solvent. Insome examples, the acid is HCl and the organic solvent is ethyl acetate.In some examples, the solvents include any mineral acid. In someexamples, the solvents include a phosphate buffer. In some examples, thesolvents include an ammonium chloride solution. In some examples, thesolvents include sulfuric acids, phosphoric acids, ammonium chloridesolutions, monobasic sodium, potassium phosphate (e.g., NaH₂PO₄)solutions, or combinations thereof. In some examples, the sulfuric acidis H₂SO₄. In some other examples, the phosphoric acid is H₃PO₄

In some examples, compound (4) is made by contacting compound (3):

with a methanolic base according to a step described in Grover et al. inJ. Org. Chem. 65: 6283-6287 (2000). In some examples, dioxalan-4-one isreacted with KOH in MeOH to form the S-enantiomer of cyclopentylmandelicacid (CPMA). In some examples, about 50 mL dioxalan-4-one is reactedwith about 270 mmols KOH in 100 mL MeOH to form the S-enantiomer ofcyclopentylmandelic acid (CPMA).

In some examples of making compound (4), the processes includecrystallizing the compound (4). In some examples, compound (3) is madeby contacting compound (2) with an alkali metal amide and cyclopentylbromide. In some examples, the alkali metal amide is selected fromlithium diisopropyl amide (LDA), lithium bis(trimethylsilyl)amide(LiHMDS), sodium bis(trimethylsilyl)amide (NaHMDS), or potassiumbis(trimethylsilyl)amide (KHMDS). In some examples, the alkali metalamide is lithium diisopropyl amide (LDA). In some examples, the alkalimetal amide is sodium bis(trimethylsilyl)amide (NaHMDS). In someexamples, the alkali metal amide is potassium bis(trimethylsilyl)amide(KHMDS).

In some examples, compound (3) is made by contacting compound (2) withLiHMDS and cyclopentyl bromide.

In some examples, compound (3) is made by contacting compound (2) withLiHMDS at −78° C., using lithium bis-(trimethylsilyl)amide in hexanesolution (e.g., 1.0 M in hexane), followed by stirring for 1 h. In someexamples, the processes further include adding cyclopentyl bromide (168mmol). In some examples, the completion of the reaction may be followedby TLC.

In some examples, compound (2) is made by contacting compound (1) withpivaldehyde to form compound (2).

In some examples, the process making compound (2) is carried out in oneor more solvents. The solvent(s) can be any solvent deemed suitable tothose of skill in the art for carrying out the reaction. In certainembodiments, the solvent(s) does not appreciably react with the compound(1) or pivaldehyde. In certain embodiments, the solvent(s) is selectedfrom alkanes such as, but not limited to, pentane, hexane, n-heptaneisomers thereof, and combinations thereof. In some other examples, thesolvent is toluene, ethylbenzene, chlorobenzene, xylenes, orcombinations thereof. In other examples, the solvent is an ether suchas, but not limited to, THF, MeTHF or MTBE. In some examples, thesolvent is any combination of the aforementioned solvents.

In particular embodiments, the solvent is hexane.

The concentration of the compounds (1) or pivaldehyde is about 0.1M toabout 2M. In some examples, a modest excess of the compounds (1) orpivaldehyde is used. The process for making compound (2) is carried outat any temperature deemed suitable by those of skill in the art. Inparticular embodiments, the reaction is conducted at any temperaturefrom about 0° C. to about 80° C., from about 10° C. to about 75° C.,from about 20° C. to about 65° C., or from about 30° C. to about 55° C.In particular embodiments, the reaction is at room temperature. Inparticular embodiments, the reaction is at about 20° C., about 21° C.,about 22° C., about 23° C., about 24° C., about 25° C., about 26° C.,about 27° C., about 28° C., about 29° C., about 30° C., about 31° C.,about 32° C., about 33° C., about 34° C., about 35° C., about 36° C.,about 37° C., about 38° C., about 39° C., about 40° C., about 41° C.,about 42° C., about 43° C., about 44° C., about 45° C., about 46° C.,about 47° C., about 48° C., about 49° C., about 50° C., about 51° C.,about 52° C., about 53° C., about 54° C., about 55° C., about 56° C.,about 57° C., about 58° C., about 59° C., about 60° C., about 61° C.,about 62° C., about 63° C., about 64° C., about 65° C., about 66° C.,about 67° C., about 68° C., about 69° C., about 70° C., about 71° C.,about 72° C., about 73° C., about 74° C., about 75° C., about 76° C.,about 77° C., about 78° C., about 79° C., about 80° C., about 81° C.,about 82° C., about 83° C., about 84° C., or about 85° C.

The process for making compound (2) is carried out in any volume deemedsuitable by those of skill in the art and depends on the size of thereaction. In particular embodiments, the reaction volume is at leastabout 50 mL, at least about 100 mL, at least about 150 mL, at leastabout 200 mL, at least about 225 mL, at least about 250 mL, at leastabout 500 mL, at least about 1 L, at least about 2 L, at least about 3L, at least about 4 L, or at least about 5 L. In another embodiment, thereaction volume is at least about 200 mL to at least about 10,000 L. Inanother embodiment, the reaction volume is at least about 1000 L, atleast about 5000 L, or at least about 10,000 L.

The reaction above can proceed for any time deemed suitable forformation of compound (2). In particular embodiments, the reactionproceeds for about 1 hour, about 2 hours, about 3 hours, about 4 hours,about 5 hours, or about 6 hours. In particular embodiments, the reactionproceeds for about 1 to about 6 hours, in another embodiment about 1 toabout 4 hours, in another embodiment about 2 to about 4 hours, inanother embodiment about 2.5 to about 3.5 hours. Reaction progress canbe monitored by standard techniques such as thin layer chromatography orhigh-performance liquid chromatography. In some examples, the processesfor making compounds (2) include stirring the reaction, for smalllaboratory scale production, or agitating the reaction for pilot orlarge scale commercial production.

The process making compound (2) is carried out in one or more solvents.The solvent(s) can be any solvent deemed suitable to those of skill inthe art for carrying out the reaction. In certain embodiments, thesolvent(s) does not appreciably react with the compound compounds (1) orpivaldehyde. In particular embodiments, the solvent is hexane. In someexamples, the solvent is selected from the group consisting of ethers,esters, aromatics, alkanes, chlorinated solvents and ketones. In someexamples, the solvent is selected from the group consisting ofN-methyl-pyrrolidone (NMP), dimethyl formamide (DMF) anddimethylacetamide (DMAC). In some examples, when the solvent is anether, the solvent is selected from tetrahydrofuran (THF), methyltetrahydrofuran (MeTHF), methyl tert-butyl ethyl (MTBE), andcombinations thereof. In some examples, when the solvent is an ester,the solvent is selected from ethyl acetate, isopropyl acetate, andcombinations thereof. In some examples, when the solvent is an aromatic,the solvent is selected from toluene, chlorobenzene, xylenes, andcombinations thereof. In some examples, when the solvent is an alkane,the solvent is selected from pentane, hexane, heptane, and combinationsthereof. In some examples, when the solvent is a chlorinated solvent,the solvent is selected from dichloromethane, chloroform, andcombinations thereof. In some examples, when the solvent is a ketone,the solvent is selected from methyl ethyl ketone (MEK). In someexamples, the solvent in a combination of any of the aforementionedsolvents. In some examples, the solvent is a combination of any of theabove ethers, esters, aromatics, alkanes, chlorinated solvents andketone solvents. In some examples, the solvent is selected from NMP,DMF, DMAC, THF, MeTHF, MTBE, ethyl acetate, isopropyl acetate, toluene,chlorobenzene, xylenes, pentane, hexane, heptane, dichloromethane,chloroform, methyl ethyl ketone, and combinations thereof. In someexamples, the solvent includes NMP, DMF, DMAC, THF, MeTHF, MTBE, ethylacetate, isopropyl acetate, toluene, chlorobenzene, xylenes, pentane,hexane, heptane, dichloromethane, chloroform, methyl ethyl ketone, orcombinations thereof.

The process for making compound (2) is carried out at any temperaturedeemed suitable by those of skill in the art. In particular embodiments,the reaction is conducted at any temperature from about 0° C. to about80° C., from about 10° C. to about 75° C., from about 20° C. to about65° C., or from about 30° C. to about 55° C. In particular embodiments,the reaction is at room temperature. In particular embodiments, thereaction is at about 20° C., about 21° C., about 22° C., about 23° C.,about 24° C., about 25° C., about 26° C., about 27° C., about 28° C.,about 29° C., about 30° C., about 31° C., about 32° C., about 33° C.,about 34° C., about 35° C., about 36° C., about 37° C., about 38° C.,about 39° C., about 40° C., about 41° C., about 42° C., about 43° C.,about 44° C., about 45° C., about 46° C., about 47° C., about 48° C.,about 49° C., about 50° C., about 51° C., about 52° C., about 53° C.,about 54° C., about 55° C., about 56° C., about 57° C., about 58° C.,about 59° C., about 60° C., about 61° C., about 62° C., about 63° C.,about 64° C., about 65° C., about 66° C., about 67° C., about 68° C.,about 69° C., about 70° C., about 71° C., about 72° C., about 73° C.,about 74° C., about 75° C., about 76° C., about 77° C., about 78° C.,about 79° C., about 80° C., about 81° C., about 82° C., about 83° C.,about 84° C., or about 85° C.

The method of making compound (2) is carried out in any volume deemedsuitable by those of skill in the art and depends on the size of thereaction. In particular embodiments, the reaction volume is at leastabout 50 mL, at least about 100 mL, at least about 150 mL, at leastabout 200 mL, at least about 225 mL, at least about 250 mL, at leastabout 500 mL, at least about 1 L, at least about 2 L, at least about 3L, at least about 4 L, or at least about 5 L. In another embodiment, thereaction volume is at least about 200 mL to at least about 10,000 L. Inanother embodiment, the reaction volume is at least about 1000 L, atleast about 5000 L, or at least about 10,000 L

The reaction above can proceed for any time deemed suitable forformation of compound (2). In particular embodiments, the reactionproceeds for about 1 hour, about 2 hours, about 3 hours, about 4 hours,about 5 hours, or about 6 hours. In particular embodiments, the reactionproceeds for about 1 to about 6 hours, in another embodiment about 1 toabout 4 hours, in another embodiment about 2 to about 4 hours, inanother embodiment about 2.5 to about 3.5 hours. Reaction progress canbe monitored by standard techniques such as thin layer chromatography orhigh-performance liquid chromatography.

In some examples, the reaction is monitored by observing the consumptionof reagents by TLC.

The method making compound (3) is carried out in hexane. The solvent(s)can be any solvent deemed suitable to those of skill in the art forcarrying out the reaction. In certain embodiments, the solvent(s) doesnot appreciably react with the compound (2), LiHMDS, orcyclopropyl-bromide. In particular embodiments, the solvent is hexane.

In some examples, the solvent is selected from the group consisting ofethers, esters, aromatics, alkanes, chlorinated solvents and ketones. Insome examples, the solvent is selected from the group consisting ofN-methyl-pyrrolidone (NMP), dimethyl formamide (DMF) anddimethylacetamide (DMAC). In some examples, when the solvent is anether, the solvent is selected from tetrahydrofuran (THF), methyltetrahydrofuran (MeTHF), methyl tert-butyl ethyl (MTBE), andcombinations thereof. In some examples, when the solvent is an ester,the solvent is selected from ethyl acetate, isopropyl acetate, andcombinations thereof. In some examples, when the solvent is an aromatic,the solvent is selected from toluene, chlorobenzene, xylenes, andcombinations thereof. In some examples, when the solvent is an alkane,the solvent is selected from pentane, hexane, heptane, and combinationsthereof. In some examples, when the solvent is a chlorinated solvent,the solvent is selected from dichloromethane, chloroform, andcombinations thereof. In some examples, when the solvent is a ketone,the solvent is selected from methyl ethyl ketone (MEK). In someexamples, the solvent in a combination of any of the aforementionedsolvents. In some examples, the solvent is a combination of any of theabove ethers, esters, aromatics, alkanes, chlorinated solvents andketone solvents. In some examples, the solvent is selected from NMP,DMF, DMAC, THF, MeTHF, MTBE, ethyl acetate, isopropyl acetate, toluene,chlorobenzene, xylenes, pentane, hexane, heptane, dichloromethane,chloroform, methyl ethyl ketone, and combinations thereof. In someexamples, the solvent includes NMP, DMF, DMAC, THF, MeTHF, MTBE, ethylacetate, isopropyl acetate, toluene, chlorobenzene, xylenes, pentane,hexane, heptane, dichloromethane, chloroform, methyl ethyl ketone, orcombinations thereof.

The process for making compound (3) is preferably carried out with abase. In particular embodiments, the base is selected from the groupconsisting of sodium hydroxide and potassium hydroxide.

The concentration of the compounds (2), LiHMDS, or cyclopropyl-bromideis about 0.01M to about 2M. The process for making compound (3) iscarried out at any temperature deemed suitable by those of skill in theart. In some examples, the reaction is initiated at low temperatures,e.g., −78° C. or about −70 to −80° C. In some examples, the reaction isslowly warmed slowly to room temperature with continuous stirring. Inparticular embodiments, the reaction is conducted at any temperaturefrom about −80° C. to about 25° C., from about −70° C. to about 25° C.,from about −60° C. to about 25° C., or from about −50° C. to about 25°C. The process for making compound (3) is carried out in any volumedeemed suitable by those of skill in the art and depends on the size ofthe reaction. In particular embodiments, the reaction volume is at leastabout 50 mL, at least about 100 mL, at least about 150 mL, at leastabout 200 mL, at least about 225 mL, at least about 250 mL, at leastabout 500 mL, at least about 1 L, at least about 2 L, at least about 3L, at least about 4 L, or at least about 5 L. In another embodiment, thereaction volume is at least about 200 mL to at least about 10,000 L. Inanother embodiment, the reaction volume is at least about 1000 L, atleast about 5000 L, or at least about 10,000 L. The reaction above canproceed for any time deemed suitable for formation of compound (3). Inparticular embodiments, the reaction proceeds for about 1 hour, about 2hours, about 3 hours, about 4 hours, about 5 hours, or about 6 hours. Inparticular embodiments, the reaction proceeds for about 1 to about 6hours, in another embodiment about 1 to about 4 hours, in anotherembodiment about 2 to about 4 hours, in another embodiment about 2.5 toabout 3.5 hours. Reaction progress can be monitored by standardtechniques such as thin layer chromatography or high-performance liquidchromatography. In some examples, the reaction is monitored by observingthe consumption of reagents by TLC.

In some examples, the compound of Formula (Ib) is compound (7):

In some examples, compound (7) is made by contacting compound (6) with areducing agent:

The method making compound (7) may be carried out in one or more aproticnon-halogenated solvents. In other examples, the solvent(s) can be anysolvent deemed suitable to those of skill in the art for carrying outthe reaction. In certain embodiments, the solvent(s) is selected fromthe group consisting of hydrocarbon solvents such as, but not limitedto, pentane(s), hexane(s), heptane(s), aromatic hydrocarbon solventssuch as, but not limited to, toluene, xylene(s), ether solvents such as,but not limited to, THF, MTBE, methyl-THF, and combinations thereof. Inparticular embodiments, the solvent is a mixture of toluene and THF.For, instance, the solvent can be 50% toluene v/v and 50% THF v/v. Inparticular embodiments, the solvent is toluene.

In some examples, the solvent is selected from the group consisting ofethers, esters, aromatics, alkanes, and ketones. In some examples, thesolvent is selected from the group consisting of N-methyl-pyrrolidone(NMP), dimethyl formamide (DMF) and dimethylacetamide (DMAC). In someexamples, when the solvent is an ether, the solvent is selected fromtetrahydrofuran (THF), methyl tetrahydrofuran (MeTHF), methyl tert-butylethyl (MTBE), and combinations thereof. In some examples, when thesolvent is an ester, the solvent is selected from ethyl acetate,isopropyl acetate, and combinations thereof. In some examples, when thesolvent is an aromatic, the solvent is selected from toluene, xylenes,and combinations thereof. In some examples, when the solvent is analkane, the solvent is selected from pentane, hexane, heptane, andcombinations thereof. In some examples, when the solvent is a ketone,the solvent is selected from methyl ethyl ketone (MEK). In someexamples, the solvent in a combination of any of the aforementionedsolvents. In some examples, the solvent is a combination of any of theabove ethers, esters, aromatics, alkanes, and ketone solvents. In someexamples, the solvent is selected from NMP, DMF, DMAC, THF, MeTHF, MTBE,ethyl acetate, isopropyl acetate, toluene, xylenes, pentane, hexane,heptane, methyl ethyl ketone, and combinations thereof. In someexamples, the solvent includes NMP, DMF, DMAC, THF, MeTHF, MTBE, ethylacetate, isopropyl acetate, toluene, xylenes, pentane, hexane, heptane,methyl ethyl ketone, or combinations thereof.

The process for making compound (7) is preferably carried out with areducing agent.

The concentration of the compounds (6) is about 0.1M to about 2M. Theprocess for making compound (7) is carried out at any temperature deemedsuitable by those of skill in the art. In particular embodiments, thereaction is conducted at any temperature from about 0° C. to about 80°C., from about 10° C. to about 75° C., from about 20° C. to about 65°C., or from about 30° C. to about 55° C. In particular embodiments, thereaction is at room temperature. In particular embodiments, the reactionis at about 20° C., about 21° C., about 22° C., about 23° C., about 24°C., about 25° C., about 26° C., about 27° C., about 28° C., about 29°C., about 30° C., about 31° C., about 32° C., about 33° C., about 34°C., about 35° C., about 36° C., about 37° C., about 38° C., about 39°C., about 40° C., about 41° C., about 42° C., about 43° C., about 44°C., about 45° C., about 46° C., about 47° C., about 48° C., about 49°C., about 50° C., about 51° C., about 52° C., about 53° C., about 54°C., about 55° C., about 56° C., about 57° C., about 58° C., about 59°C., about 60° C., about 61° C., about 62° C., about 63° C., about 64°C., about 65° C., about 66° C., about 67° C., about 68° C., about 69°C., about 70° C., about 71° C., about 72° C., about 73° C., about 74°C., about 75° C., about 76° C., about 77° C., about 78° C., about 79°C., about 80° C., about 81° C., about 82° C., about 83° C., about 84°C., or about 85° C.

The process for making compound (7) is carried out in any volume deemedsuitable by those of skill in the art and depends on the size of thereaction. In particular embodiments, the reaction volume is at leastabout 50 mL, at least about 100 mL, at least about 150 mL, at leastabout 200 mL, at least about 225 mL, at least about 250 mL, at leastabout 500 mL, at least about 1 L, at least about 2 L, at least about 3L, at least about 4 L, or at least about 5 L. In another embodiment, thereaction volume is at least about 200 mL to at least about 10,000 L. Inanother embodiment, the reaction volume is at least about 1000 L, atleast about 5000 L, at least about 10,000 L, at least about 25,000 L, atleast about 50,000 L, at least about 75,000 L, or at least about 10,000L.

The reaction above can proceed for any time deemed suitable forformation of compound (7). In particular embodiments, the reactionproceeds for about 1 hour, about 2 hours, about 3 hours, about 4 hours,about 5 hours, or about 6 hours. In particular embodiments, the reactionproceeds for about 1 to about 6 hours, in another embodiment about 1 toabout 4 hours, in another embodiment about 2 to about 4 hours, inanother embodiment about 2.5 to about 3.5 hours. Reaction progress canbe monitored by standard techniques such as thin layer chromatography orhigh-performance liquid chromatography.

The processes herein may further include stirring or agitating as thereaction proceeds.

In some examples, compound (6) is made by contacting R(−)-malic acid,compound (5), with methyl amine:

The method making compound (6) is carried out in one or more solvents.The solvent(s) can be any solvent deemed suitable to those of skill inthe art for carrying out the reaction. In certain embodiments, thesolvent(s) does not appreciably react with the compound (5) ormethyl-amine. In certain embodiments, the solvent(s) allows theazeotropic removal of water but does not participate in the reaction. Incertain embodiments, the solvent(s) is selected from toluene.

The concentration of the compounds (5) or methyl-amine is about 0.1M toabout 2M. In some examples, a slight excess of methylamine is used toavoid the formation of the diamide over the imide. In some examples, theexcess amount of methylamine is 10-20% molar excess.

The process for making compound (5) is carried out at any temperaturedeemed suitable by those of skill in the art. In particular embodiments,the reaction is conducted at any temperature from about 0° C. to about80° C., from about 10° C. to about 75° C., from about 20° C. to about65° C., or from about 30° C. to about 55° C. In particular embodiments,the reaction is at room temperature. In particular embodiments, thereaction is at about 20° C., about 21° C., about 22° C., about 23° C.,about 24° C., about 25° C., about 26° C., about 27° C., about 28° C.,about 29° C., about 30° C., about 31° C., about 32° C., about 33° C.,about 34° C., about 35° C., about 36° C., about 37° C., about 38° C.,about 39° C., about 40° C., about 41° C., about 42° C., about 43° C.,about 44° C., about 45° C., about 46° C., about 47° C., about 48° C.,about 49° C., about 50° C., about 51° C., about 52° C., about 53° C.,about 54° C., about 55° C., about 56° C., about 57° C., about 58° C.,about 59° C., about 60° C., about 61° C., about 62° C., about 63° C.,about 64° C., about 65° C., about 66° C., about 67° C., about 68° C.,about 69° C., about 70° C., about 71° C., about 72° C., about 73° C.,about 74° C., about 75° C., about 76° C., about 77° C., about 78° C.,about 79° C., about 80° C., about 81° C., about 82° C., about 83° C.,about 84° C., or about 85° C.

The process for making compound (5) is carried out in any volume deemedsuitable by those of skill in the art and depends on the size of thereaction. In particular embodiments, the reaction volume is at leastabout 50 mL, at least about 100 mL, at least about 150 mL, at leastabout 200 mL, at least about 225 mL, at least about 250 mL, at leastabout 500 mL, at least about 1 L, at least about 2 L, at least about 3L, at least about 4 L, or at least about 5 L. In another embodiment, thereaction volume is at least about 200 mL to at least about 10,000 L. Inanother embodiment, the reaction volume is at least about 1000 L, atleast about 5000 L, or at least about 10,000 L.

The reaction above can proceed for any time deemed suitable forformation of compound (5). In particular embodiments, the reactionproceeds for about 1 hour, about 2 hours, about 3 hours, about 4 hours,about 5 hours, or about 6 hours. In particular embodiments, the reactionproceeds for about 1 to about 6 hours, in another embodiment about 1 toabout 4 hours, in another embodiment about 2 to about 4 hours, inanother embodiment about 2.5 to about 3.5 hours. Reaction progress canbe monitored by standard techniques such as thin layer chromatography orhigh-performance liquid chromatography.

In some examples, R(−)-malic acid, compound (5), is made by isolatingR(−)-malic acid, compound (5), from a mixture comprising compound (5).In some examples, R(−)-malic acid is sourced commercially.

In some examples, R(−)-malic acid, compound (5), is made by isolatingR(−)-malic acid, compound (5), from a racemic mixture comprisingcompound (5). In some examples, R(−)-malic acid is sourced commercially.

In any of the above reaction steps, the reaction progress can bemonitored by standard techniques such as thin layer chromatography, gaschromatography, or high-performance liquid chromatography. In someexamples, the reaction is monitored by observing the consumption ofreagents by TLC.

C. PROCESS FOR MAKING R-1-METHYL-PYRROLIDIN-3-OL

In certain examples herein, the disclosure sets forth a process formaking a compound of Formula (Ib):

In some examples, R¹ is alkyl. In some examples, the processes includeproviding a compound (5):

In some examples, the processes include contacting compound (5) with analkyl-amine to form a compound of Formula Ibc:

In some examples, the alkylamine is methyl amine and R¹ is methyl. Insome examples, the processes further include contacting compound (Ibc)with a reducing agent to form a compound of Formula (Ib):

In some examples, R¹ is alkyl. In other examples, R¹ is methyl, ethyl,n-propyl, i-propyl, n-butyl, t-butyl, i-butyl, n-pentyl, or i-pentyl. Incertain examples, R¹ is methyl or ethyl. In some examples, R¹ is methyl.In certain examples, R¹ is ethyl. In some examples, the compound ofFormula (Ib) is compound (7):

In some examples, compound (6) is made by contacting R(−)-malic acid,compound (5), with methyl amine:

In some of these examples, R(−)-malic acid, compound (5), is made byisolating R(−)-malic acid, compound (5), from a mixture of R(−)-malicacid and L(+)-malic acid. In some other of these examples, R(−)-malicacid, compound (5), is made by isolating R(−)-malic acid, compound (5),from a racemic mixture comprising compound (5).

In certain examples, R-1-methyl-pyrrolidin-3-ol can be preparedaccording to processes known to those of skill. For example,R-1-methyl-pyrrolidin-3-ol can be prepared using alkyl halides followingby chiral resolution of the R-enantiomer. Other useful approaches areset forth in EP 0 269 358. See, also US Patent Application PublicationNo. 2007/0123557.

D. COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS MADE BY THE PROCESSES SETFORTH HEREIN

In some examples, set forth herein are compounds, mixtures of compounds,mixtures of stereoisomers, or combinations thereof, wherein thecompounds, mixtures of compounds, mixtures of stereoisomers are preparedby the processes set forth herein.

In some examples, provided herein are products of the processes above.

In some examples, provided herein are products of the processes formaking a compound of Formula (I):

wherein:

-   -   R¹ and R² are each, independently in each instance, selected        from alkyl and alkyl substituted with alkoxycarbonyl;    -   the stereochemical configuration about the carbon atom indicated        by 2 is R;    -   the stereochemical configuration about carbon atom indicated by        3′ is R; and        X⁻ is an anion.

In some examples, provided herein are products of the processes formaking a compound of Formula (Ib):

wherein R¹ is selected from the group consisting of alkyl.

In some examples, the carbon indicated by 2 has (R) stereochemistry andthe carbon indicated by *3′ has (R) stereochemistry. In some examples,R¹ is methyl. In some examples, R¹ is ethyl. In some examples, R¹ ismethyl. In some examples, R¹ is —CH₂C(O)OCH₂CH₃.

In some examples, the carbon indicated by 2 has (R) stereochemistry, thecarbon indicated by *3′ has (R) stereochemistry, and the carbonindicated by *1′ has (R) or (S) stereochemistry. In some examples, R¹ ismethyl. In some examples, R¹ is ethyl.

In some examples, the carbon indicated by 2 has (R) stereochemistry, thecarbon indicated by *3′ has (R) stereochemistry, and the carbonindicated by *1′ has (R) stereochemistry. In some examples, R¹ ismethyl. In some examples, R¹ is ethyl.

In some examples, the carbon indicated by 2 has (R) stereochemistry, thecarbon indicated by *3′ has (R) stereochemistry, and the carbonindicated by *1′ has (S) stereochemistry. In some examples, R¹ ismethyl. In some examples, R¹ is ethyl.

In some examples, the compound of Formula (I) is

In some examples, the compound of Formula (I) is

In some examples, the compound of Formula (I) is

In some examples, set forth herein is a composition including a mixtureof compounds having following structures (Ia1a) and (Ia2b):

In some examples, the compounds of structures (Ia1) and (Ia2) areprepared by a process set forth herein. In some examples, the compoundsare formulated with a pharmaceutically acceptable excipient, diluent, orsalt.

In some examples, the compounds of structures (Ia1a) and (Ia2b) areprepared by a method set forth herein. In some examples, the compoundsare formulated with a pharmaceutically acceptable excipient, diluent, orsalt.

In some examples, set forth herein is a pharmaceutical composition,include a compound prepared by a method set forth herein. In someexamples, the composition is formulated as a topical.

In some examples, set forth herein are polymorphs, co-crystals, hydratesand solvates which include a compound prepared by a method set forthherein.

In some examples, set forth herein are polymorphs, co-crystals, hydratesand solvates which include a compound prepared by a process, wherein theprocess is for making a compound of Formula (I).

In some examples, set forth herein are polymorphs, co-crystals, hydratesand solvates which include a compound prepared by a process, wherein theprocess is for making a compound of Formula (II).

E. Methods of Using Glycopyrronium Salts

The present disclosure sets forth methods of treating diseases,conditions, or disorders, e.g., hyperhidrosis, including administering atherapeutically effective amount or one or more of the compoundsdisclosed herein such as, but not limited to, a glycopyrronium compound(e.g. a glycopyrronium salt such as3′(R)-[R-Cyclopentylphenylhydroxyacetoy]-1′-ethyl-1′methoxycarbonylpyrrolidiniumbromide) to a subject in need thereof. Diseases, disorders, and/orconditions include, but are not limited to, those associated withhyperhidrosis or anxiety. Diseases, disorders, and/or conditionsinclude, but are not limited to, any indications for whichanticholinergics are therapeutic. In some examples herein, methods oftreating diseases, conditions, or disorders include treatinggastrointestinal disorders. In some examples herein, methods of treatingdiseases, conditions, or disorders include treating gastrointestinaldisorders selected from gastritis, diarrhea, pylorospasm,diverticulitis, ulcerative colitis, nausea, and vomiting.

In some examples herein, methods of treating diseases, conditions, ordisorders include treating genitourinary disorders. In some examplesherein, methods of treating diseases, conditions, or disorders includetreating genitourinary disorders selected from cystitis, urethritis, andprostatitis.

In some examples herein, methods of treating diseases, conditions, ordisorders include treating respiratory disorders. In some examplesherein, methods of treating diseases, conditions, or disorders includetreating respiratory disorders selected from asthma, chronic bronchitis,and chronic obstructive pulmonary disease (COPD).

In some examples herein, methods of treating diseases, conditions, ordisorders include treating sinus bradycardia due to a hypersensitivevagus nerve.

In some examples herein, methods of treating diseases, conditions, ordisorders include treating insomnia. In some examples herein, methods oftreating diseases, conditions, or disorders include treating insomnia ona short-term basis.

In some examples herein, methods of treating diseases, conditions, ordisorders include treating dizziness. In some examples herein, methodsof treating diseases, conditions, or disorders include treating vertigo.In some examples herein, methods of treating diseases, conditions, ordisorders include ameliorating motion sickness-related symptoms.

In some examples herein, methods of treating diseases, conditions, ordisorders include producing antisialagogue effects. In some examplesherein, methods of treating diseases, conditions, or disorders includemediating saliva production. In some examples herein, methods oftreating diseases, conditions, or disorders include providing a sedativeeffect.

Herein, subjects include mammals, generally, as well as humans,specifically, but necessarily limited to humans. In some examples, thesubject is characterized by a particular patient population, e.g., men,women, adults, children, or persons having a condition such as, but notlimited to, hyperhidrosis.

In some examples, set forth herein is a method of treatinghyperhidrosis, include administering to a subject in need thereof acomposition include a compound prepared by a method set forth herein ora composition set forth herein.

In some examples, set forth herein is a method of treating a disease ordisorder marked by a need for an anticholinergic agent, includingadministering to a subject in need thereof a composition include acompound prepared by a process set forth herein or a composition setforth herein.

In some examples herein, the subject is a mammal. In certain examples,the subject is a human. In certain other examples, the human hashyperhidrosis. In certain other examples, the human suffers fromhyperhidrosis.

The compounds described herein can be administered alone or togetherwith one or more additional therapeutic agents. The one or moreadditional therapeutic agents can be administered just prior to,concurrent with, or shortly after the administration of the compoundsdescribed herein. The present disclosure also includes pharmaceuticalcompositions comprising any of the compounds described herein incombination with one or more additional therapeutic agents, and methodsof treatment comprising administering such combinations to subjects inneed thereof.

The present disclosure includes pharmaceutical compositions of thecompounds described herein, e.g., compositions comprising a compounddescribed herein, a salt, stereoisomer, mixture of stereoisomers,polymorph thereof, and a pharmaceutically acceptable carrier, diluent,and/or excipient. Examples of suitable carriers, diluents and excipientsinclude, but are not limited to: buffers for maintenance of propercomposition pH (e.g., citrate buffers, succinate buffers, acetatebuffers, phosphate buffers, lactate buffers, oxalate buffers and thelike), carrier proteins (e.g., human serum albumin), saline, polyols(e.g., trehalose, sucrose, xylitol, sorbitol, and the like), surfactants(e.g., polysorbate 20, polysorbate 80, polyoxolate, and the like),antimicrobials, and antioxidants.

In another aspect of the invention is a pharmaceutical compositioncomprising a polymorphic or amorphous form of a compound describedherein, including any of the foregoing or hereafter embodiments, and apharmaceutically acceptable carrier.

The compounds or compositions described herein can be formulated aspharmaceutical compositions by formulation with additives such aspharmaceutically acceptable excipients, pharmaceutically acceptablecarriers, and pharmaceutically acceptable vehicles. Suitablepharmaceutically acceptable excipients, carriers and vehicles includeprocessing agents and drug delivery modifiers and enhancers, such as,for example, calcium phosphate, magnesium stearate, talc,monosaccharides, disaccharides, starch, gelatin, cellulose, methylcellulose, sodium carboxymethyl cellulose, dextrose,hydroxypropyl-β-cyclodextrin, polyvinylpyrrolidinone, low melting waxes,ion exchange resins, and the like, as well as combinations of any two ormore thereof. Other suitable pharmaceutically acceptable excipients aredescribed in “Remington's Pharmaceutical Sciences,” Mack Pub. Co., NewJersey (1991), and “Remington: The Science and Practice of Pharmacy,”Lippincott Williams & Wilkins, Philadelphia, 20th edition (2003) and21st edition (2005), incorporated herein by reference in its entiretyfor all purposes.

A pharmaceutical composition can comprise a unit dose formulation, wherethe unit dose is a dose sufficient to have a therapeutic or suppressiveeffect or an amount effective to modulate or treat a disease orcondition described herein. The unit dose may be sufficient as a singledose to have a therapeutic or suppressive effect or an amount effectiveto modulate or treat a disease or condition described herein.Alternatively, the unit dose may be a dose administered periodically ina course of treatment or suppression of a disorder, or to modulate ortreat a disease or condition described herein.

Pharmaceutical compositions containing the compounds or compositions ofthe invention may be in any form suitable for the intended method ofadministration, including, for example, a solution, a suspension, or anemulsion. In some examples, the compositions set forth herein aresuitable for topical application. In some examples, liquid carriers aretypically used in preparing solutions, suspensions, and emulsions.Liquid carriers contemplated for use in the practice of the presentinvention include, for example, water, saline, pharmaceuticallyacceptable organic solvent(s), pharmaceutically acceptable oils or fats,and the like, as well as mixtures of two or more thereof. The liquidcarrier may contain other suitable pharmaceutically acceptable additivessuch as solubilizers, emulsifiers, nutrients, buffers, preservatives,suspending agents, thickening agents, viscosity regulators, stabilizers,and the like. Suitable organic solvents include, for example, monohydricalcohols, such as ethanol, and polyhydric alcohols, such as glycols.Suitable oils include, for example, soybean oil, coconut oil, olive oil,safflower oil, cottonseed oil, and the like.

The compounds or compositions of the invention may be administeredtopically in dosage unit formulations containing conventional nontoxicpharmaceutically acceptable carriers, adjuvants, and vehicles asdesired. For example, suitable modes of administration includetransdermal or transmucosal, intranasal (e.g., via nasal mucosa), andthe like, and directly to a specific or affected site on the subject.Topical administration may also involve the use of transdermaladministration such as transdermal patches or iontophoresis devices. Thecompounds or compositions are mixed with pharmaceutically acceptablecarriers, adjuvants, and vehicles appropriate for the desired route ofadministration. The compounds described for use herein can beadministered in solid form, in liquid form, in aerosol form, or in theform of tablets, pills, powder mixtures, capsules, granules, creams,solutions, emulsions, dispersions, and in other suitable forms. Thecompounds can also be administered as prodrugs, where the prodrugundergoes transformation in the treated subject to a form which istherapeutically effective. Additional methods of administration areknown in the art.

F. EXAMPLES

Unless otherwise stated, chemical reagents were purchased fromcommercially available sources.

Reagents used herein are available from commercial vendors and werepurchased from commercially available sources unless specified hereinotherwise or unless the preparation of the reagent(s) is/are describedherein.

Example 1

The below synthetic description refers to the numbered compoundsillustrated in FIG. 1. Numbers which refer to these compounds in FIG. 1are bolded and underlined in this Example.

Synthesis of R(−)-Cyclopentylmandelic acid (4)

R(−)-cyclopentylmandelic acid (compound 4) can be synthesized startingwith R(−)-mandelic acid (compound 1) according to the scheme in FIG. 1.Compounds 1 and 4 can also be purchased from Sigma-Aldrich.

Step 1: Making Compound 2.

R(−)-mandelic acid (1) was suspended in hexane and mixed withpivaldehyde and a catalytic amount of trifluoromethanesulfonic acid atroom temperature to form a mixture. Specifically, R(−)-mandelic acid inhexane suspension (50 g, 328 mmol) was mixed with pivaldehyde (42.7 ml,396 mmol) then trifluoromethanesulfonic acid (1.23 ml, 14 mmol) at roomtemperature. The mixture was warmed to 36° C. and then allowed to reactfor about 5 hours. The reaction was followed by TLC for 5 hours until nostarting material could be detected. The mixture was then cooled to roomtemperature. The mixture was then cooled to room temperature and treatedwith 8% aqueous sodium bicarbonate. The aqueous layer was removed andthe organic layer dried over anhydrous sodium sulfate. After filtrationand removal of the solvent under vacuum, the crude product wasrecrystallized to give (5R)-2-(tert-butyl)-5-phenyl-1,3-dioxolan-4-one(compound 2) in 88% yield (per S-enantiomer yield).

Step 2: Making Compound 3.

Generally, compound 2 was reacted with lithium hexamethyl disilazide(LiHMDS) in hexane at −78° C. under stirring for one hour. Next,cyclopentyl bromide was added to the reaction of compound 2 with LiHMDS.The reaction was kept cool for about four (4) hours and then slowlywarmed to room temperature and allowed to react for at least twelve (12)more hours. The resulting mixture was then treated with 10% aqueousammonium chloride. The aqueous layer was discarded and the organic layerdried over anhydrous sodium sulfate. The solvent was removed undervacuum and the residue recrystallized from hexane to give pure product(5R)-2-(tert-butyl)-5-cyclopentyl-5-phenyl-1,3-dioxolan-4-one (3) in 63%yield (per S-enantiomer yield). In one specific instance, at −78° C., alithium bis-(trimethylsilyl)amide in hexane solution (120 ml, 120 mmol,1.0 M in hexane) was added to compound 2 (25 g, 113.5 mmol, dissolved in100 ml of dried THF), and stirred for 1 hour, followed by addition ofcyclopentyl bromide (25 g, 168 mmol). The reaction was kept at −78° C.for 4 h, then slowly warmed up to room temperature and allowed to reactfor another 12 hours. The completion of the reaction was followed byTLC. With stirring, a solution of 10% of NH₄Cl (25 ml) was added to themixture. Then, the mixture was poured into a separation funnelcontaining 10% NH₄Cl solution (200 ml). The aqueous layer was discarded,and the organic layer was dried over Na₂SO₄. The solvent was removed togive a crude product, which was then re-crystallized in hexane to give apure product (20.36 g, yield 63%, white crystal).

Step 3: Making Compound 4.

R(−)-cyclopentylmandelic acid (compound 4) was prepared by providingcompound 3 in aqueous methanolic potassium hydroxide at 65° C. for fourhours. After cooling this mixture to room temperature and removing themethanol under vacuum, the aqueous solution was acidified with aqueoushydrochloric acid. The aqueous solution was then extracted twice withethyl acetate and the organic phase dried with anhydrous sodium sulfate.After removing the solvent and performing a recrystallization, pureR(−)-cyclopentylmandelic acid (compound 4) was obtained in 62% yield(based on S-enantiomer yield).

Synthesis of (R)-1-methylpyrrolidin-3-ol (7)

(R)-1-methylpyrrolidin-3-ol (compound 7) was prepared starting withR(−)-malic acid.

Step 4: Making Compound 6.

R(−)-malic acid (also known as (S)-2-hydroxysuccinic acid) (compound 5)was reacted with methyl amine (CH₃NH₂) to form(R)-3-hydroxy-1-methylpyrrolidine-2,5-dione (compound 6).(R)-3-hydroxy-1-methylpyrrolidine-2,5-dione (6) was treated with areducing agent to form (R)-1-methylpyrrolidin-3-ol (compound 7). In oneinstance, reduction of compound 6 was performed using NaAlH₄/LiCl. To acooled solution of lithium chloride (0.11 mol) in THF was added NaAlH₄(0.22 mol) in toluene/THF under argon. N-methylsuccinimide (0.083 mol)in THF was added while holding the temperature below 15° C. After theaddition was complete, the reaction was allowed to warm to roomtemperature. After 30 minutes at room temperature, the reaction washeated to greater than 40° C. for 2 hr. The reaction was then cooled toless than 5° C. and toluene (50 ml) was then added. Water (9 ml) wasthen added slowly holding the temperature below 15° C. Additional H₂O oraqueous NaOH was used as necessary. The insoluble inorganic salts areremoved by filtration. These solids are washed with additional THF ortoluene to obtain a solution which contained N-methyl pyrrole, asdetermined by GLC analysis.

Synthesis of 2R3′R-glycopyrrolate base (8)

Step 5: Making Compound 8.

R(−)-cyclopentylmandelic acid (4) was coupled to(R)-1-methylpyrrolidin-3-ol (2) to make the diasterically pure2R3′R-glycopyrrolate base (compound 8) using 1,1-carbonyldiimideazole(CDI) activated esterification. The R2R3′R-glycopyrrolate base (compound8) was obtained in greater than 90% yield.

Synthesis of3′(R)-[R-Cyclopentylphenylhydroxyacetoy]-1′-ethyl-1′methoxycarbonylpyrrolidiniumbromide (9)

Step 6: Making Compound 9.

The glycopyrrolate base, compound 8 ((R)-1-methylpyrrolidin-3-yl−

(R)-2-cyclopentyl-2-hydroxy-2-phenylacetate), was treated in dryacetonitrile with methyl bromoacetate at room temperature under stirringfor three (3) hours. The crude product was dissolved in a small volumeof methylene chloride and poured into dry ethyl ether to obtain aprecipitate. This procedure was repeated three times to provide(3R)-3-((R)-2-cyclopentyl-2-hydroxy-2-phenylacetoxy)-1-(2-ethoxy-2-oxoethyl)-1-methylpyrrolidin-1-iumbromide, also known as3′(R)-[R-Cyclopentylphenylhydroxyacetoy]-1′-ethyl-1′methoxycarbonylpyrrolidiniumbromide, (compound 9) in 89% yield.

Example 2

The below synthetic description refers to the numbered compoundsillustrated in FIG. 2. Numbers which refer to these compounds in FIG. 2are bolded and underlined in this Example.

Synthesis of R(−)-Cyclopentylmandelic acid (4)

R(−)-cyclopentylmandelic acid (compound 4) can be synthesized startingwith R(−)-mandelic acid (compound 1) according to Example 1.

Step 1: Making Compound 2.

R(−)-mandelic acid (1) was suspended in hexane and mixed withpivaldehyde and a catalytic amount of trifluoromethanesulfonic acid atroom temperature to form a mixture. The mixture was warmed to 36° C. andthen allowed to react for about 5 hours. The mixture was then cooled toroom temperature and treated with 8% aqueous sodium bicarbonate. Theaqueous layer was removed and the organic layer dried over anhydroussodium sulfate. After filtration and removal of the solvent undervacuum, the crude product was recrystallized to give(5R)-2-(tert-butyl)-5-phenyl-1,3-dioxolan-4-one (compound 2) in 88%yield (per S-enantiomer yield).

Step 2: Making Compound 3.

Compound 2 was reacted with lithium hexamethyl disilazide (LiHMDS) inhexane at −78° C. under stirring for one hour. Next, cyclopentyl bromidewas added to the reaction mixture including compound 2 and LiHMDS. Thereaction was kept cool for about four (4) hours and then slowly warmedto room temperature and allowed to react for at least twelve (12) morehours. The resulting mixture was then treated with 10% aqueous ammoniumchloride. The aqueous layer was discarded and the organic layer driedover anhydrous sodium sulfate. The solvent was removed under vacuum andthe residue recrystallized from hexane to give pure product(5R)-2-(tert-butyl)-5-cyclopentyl-5-phenyl-1,3-dioxolan-4-one (3) in 63%yield (per S-enantiomer yield).

Step 3: Making Compound 4.

R(−)-cyclopentylmandelic acid (compound 4) was prepared by providingcompound 3 in aqueous methanolic potassium hydroxide at 65° C. for fourhours. After cooling this mixture to room temperature and removing themethanol under vacuum, the aqueous solution was acidified with aqueoushydrochloric acid. The aqueous solution was then extracted twice withethyl acetate and the organic phase dried with anhydrous sodium sulfate.After removing the solvent and performing a recrystallization, pureR(−)-cyclopentylmandelic acid (compound 4) was obtained in 62% yield(based on S-enantiomer yield).

Next, a racemic mixture of 1-methyl-3-pyrridinol (20) was provided:

Synthesis of 2R3′R-glycopyrrolate base (8)

Step 4: Making Compound 8.

Enantiomerically pure R(−)-cyclopentylmandelic acid (4) was coupled toracemic 1-methyl-3-pyrridinol (20) using 1,1-carbonyldiimideazole (CDI)activated esterification to make an enantiomerically pure mixture of thefollowing erythro- and threo-glycopyrrolate bases (compounds 8 and 21,respectively):

The 2R3′R-glycopyrrolate base (compound 8) was then resolved using the5-nitroisophthalate salt procedure in Finnish Patent 49713, to provideenantiomerically pure 2R3′R (erythro) as well as pure 2R3′S (threo). Inthis example, the 2R3′S (threo) was discarded. The 2R3′R (erythro) wasseparated as stereomerically pure compound 8.

Step 6: Making Compound 9.

The glycopyrrolate base, compound 8, was treated in dry acetonitrilewith methyl bromoacetate at room temperature under stirring for three(3) hours. The crude product was dissolved in a small volume ofmethylene chloride and poured into dry ethyl ether to obtain aprecipitate. This procedure was repeated three times to provide(3R)-3-((R)-2-cyclopentyl-2-hydroxy-2-phenylacetoxy)-1-(2-ethoxy-2-oxoethyl)-1-methylpyrrolidin-1-iumbromide, also known as3′(R)-[R-Cyclopentylphenylhydroxyacetoy]-1′-ethyl-1′methoxycarbonylpyrrolidiniumbromide (compound 9) in 89% yield. Compound 9 included the followingstereoisomers:

Example 3

The below synthetic description refers to the numbered compoundsillustrated in FIG. 3. Numbers which refer to these compounds in FIG. 3are bolded and underlined in this Example.

Synthesis of S(+)-Cyclopentylmandelic acid (40)

S(+)-cyclopentylmandelic acid (compound 40) can be synthesized startingwith S(+)-mandelic acid (compound 10) according to the scheme in FIG. 3.Compounds 10 and 40 can be purchased from Sigma-Aldrich.

Step 1: Making Compound 25.

S(+)-mandelic acid (10) was suspended in hexane and mixed withpivaldehyde and a catalytic amount of trifluoromethanesulfonic acid atroom temperature to form a mixture. Specifically, S(+)-mandelic acid inhexane suspension (50 g, 328 mmol) was mixed with pivaldehyde (42.7 ml,396 mmol) then trifluoromethanesulfonic acid (1.23 ml, 14 mmol) at roomtemperature. The mixture was warmed to 36° C. and then allowed to reactfor about 5 hours. The reaction was followed by TLC for 5 hours until nostarting material could be detected. The mixture was then cooled to roomtemperature. The mixture was then cooled to room temperature and treatedwith 8% aqueous sodium bicarbonate. The aqueous layer was removed andthe organic layer dried over anhydrous sodium sulfate. After filtrationand removal of the solvent under vacuum, the crude product wasrecrystallized to give cis-(2R,5S)-2-tert-butyl)-5-phenyl-1,3-dioxolan-4-one (compound 25) in 88% yield(per S-enantiomer yield).

Step 2: Making Compound 30.

Generally, compound 25 was reacted with lithium hexamethyl disilazide(LiHMDS) in hexane at −78° C. under stirring for one hour. Next,cyclopentyl bromide was added to the reaction of compound 25 withLiHMDS. The reaction was kept cool for about four (4) hours and thenslowly warmed to room temperature and allowed to react for at leasttwelve (12) more hours. The resulting mixture was then treated with 10%aqueous ammonium chloride. The aqueous layer was discarded and theorganic layer dried over anhydrous sodium sulfate. The solvent wasremoved under vacuum and the residue recrystallized from hexane to givepure product(5S)-2-(tert-butyl)-5-cyclopentyl-5-phenyl-1,3-dioxolan-4-one (30). Inone specific instance, at −78° C., a lithium bis-(trimethylsilyl)amidein hexane solution (120 ml, 120 mmol, 1.0 M in hexane) was added tocompound 25 (25 g, 113.5 mmol, dissolved in 100 ml of dried THF), andstirred for 1 hour, followed by addition of cyclopentyl bromide (25 g,168 mmol). The reaction was kept at −78° C. for 4 h, then slowly warmedup to room temperature and allowed to react for another 12 hours. Thecompletion of the reaction was followed by TLC. With stirring, asolution of 10% of NH₄Cl (25 ml) was added to the mixture. Then, themixture was poured into a separation funnel containing 10% NH₄Clsolution (200 ml). The aqueous layer was discarded, and the organiclayer was dried over Na2SO4. The solvent was removed to give a crudeproduct, which was then re-crystallized in hexane to give a pure product(20.36 g, yield 63%, white crystal).

Step 3: Making Compound 40.

S(+)-cyclopentylmandelic acid (compound 40) was prepared by providingcompound 30 in aqueous methanolic potassium hydroxide at 65° C. for fourhours. After cooling this mixture to room temperature and removing themethanol under vacuum, the aqueous solution was acidified with aqueoushydrochloric acid. The aqueous solution was then extracted twice withethyl acetate and the organic phase dried with anhydrous sodium sulfate.After removing the solvent and performing a recrystallization, pureS(+)-cyclopentylmandelic acid (compound 40) was obtained.

Synthesis of (R)-1-methylpyrrolidin-3-ol (7)

(R)-1-methylpyrrolidin-3-ol (compound 7) was prepared starting withR(−)-malic acid.

Step 4: Making Compound 6.

R(−)-malic acid (also known as (S)-2-hydroxysuccinic acid) (compound 5)was reacted with methyl amine (CH₃NH₂) to form(R)-3-hydroxy-1-methylpyrrolidine-2,5-dione (compound6)-3-hydroxy-1-methylpyrrolidine-2,5-dione (6) was treated with areducing agent to form (R)-1-methylpyrrolidin-3-ol (compound 7). In oneinstance, reduction of compound 6 was performed using NaAlH₄/LiCl. To acooled solution of lithium chloride (0.11 mol) in THF was added NaAlH₄(0.22 mol) in toluene/THF under argon. N-methylsuccinimide (0.083 mol)in THF was added while holding the temperature below 15° C. After theaddition was complete, the reaction was allowed to warm to roomtemperature. After 30 minutes at room temperature, the reaction washeated to greater than 40° C. for 2 hr. The reaction was then cooled toless than 5° C. and toluene (50 ml) was then added. Water (9 ml) wasthen added slowly holding the temperature below 15° C. Additional H₂O oraqueous NaOH was used as necessary. The insoluble inorganic salts areremoved by filtration. These solids are washed with additional THF ortoluene to obtain a solution which contained N-methyl pyrrole, asdetermined by GLC analysis.

Synthesis of 2R3′R-glycopyrrolate base (80)

Step 5: Making Compound 8.

S(+)-cyclopentylmandelic acid (40) was coupled to(R)-1-methylpyrrolidin-3-ol (7) to make the diasterically pure2S3′R-glycopyrrolate base (compound 80) using 1,1-carbonyldiimideazole(CDI) activated esterification. The S2R3′R-glycopyrrolate base (compound80) was obtained in greater than 90% yield.

Synthesis of3′(R)-[S-Cyclopentylphenylhydroxyacetoy]-1′-ethyl-1′methoxycarbonylpyrrolidiniumbromide (90)

Step 6: Making Compound 90.

The glycopyrrolate base, compound 80, was treated in dry acetonitrilewith methyl bromoacetate at room temperature under stirring for three(3) hours. The crude product was dissolved in a small volume ofmethylene chloride and poured into dry ethyl ether to obtain aprecipitate. This procedure was repeated three times to provide(3R)-3-((S)-2-cyclopentyl-2-hydroxy-2-phenylacetoxy)-1-(2-ethoxy-2-oxoethyl)-1-methylpyrrolidin-1-iumbromide, also known as 3′(R)-[S-Cyclopentylphenylhydroxyacetoy]-1′-ethyl-1′methoxycarbonylpyrrolidiniumbromide (compound 90).

Example 4

The below synthetic description refers to the numbered compoundsillustrated in FIG. 4. Numbers which refer to these compounds in FIG. 4are bolded and underlined in this Example.

Synthesis of R(−)-Cyclopentylmandelic acid (4)

R(−)-cyclopentylmandelic acid (compound 4) can be synthesized startingwith R(−)-mandelic acid (compound 1) according to the scheme in FIG. 4.Compounds 1 and 4 can also be purchased from Sigma-Aldrich.

Step 1: Making Compound 2.

R(−)-mandelic acid (1) is suspended in hexane and mixed with pivaldehydeand a catalytic amount of trifluoromethanesulfonic acid at roomtemperature to form a mixture. Specifically, R(−)-mandelic acid inhexane suspension (50 g, 328 mmol) is mixed with pivaldehyde (42.7 ml,396 mmol) then trifluoromethanesulfonic acid (1.23 ml, 14 mmol) at roomtemperature. The mixture is warmed to 36° C. and then allowed to reactfor about 5 hours. The reaction is followed by TLC for 5 hours until nostarting material is detected. The mixture is then cooled to roomtemperature. The mixture is then cooled to room temperature and treatedwith 8% aqueous sodium bicarbonate. The aqueous layer is removed and theorganic layer dried over anhydrous sodium sulfate. After filtration andremoval of the solvent under vacuum, the crude product is recrystallizedto give (5R)-2-(tert-butyl)-5-phenyl-1,3-dioxolan-4-one (compound 2).

Step 2: Making Compound 3.

Generally, compound 2 is reacted with lithium hexamethyl disilazide(LiHMDS) in hexane at −78° C. under stirring for one hour. Next,cyclopentyl bromide is added to the reaction of compound 2 with LiHMDS.The reaction is kept cool for about four (4) hours and then slowlywarmed to room temperature and allowed to react for at least twelve (12)more hours. The resulting mixture is then treated with 10% aqueousammonium chloride. The aqueous layer is discarded and the organic layerdried over anhydrous sodium sulfate. The solvent is removed under vacuumand the residue recrystallized from hexane to give pure product(5R)-2-(tert-butyl)-5-cyclopentyl-5-phenyl-1,3-dioxolan-4-one (3). Inone specific instance, at −78° C., a lithium bis-(trimethylsilyl)amidein hexane solution (120 ml, 120 mmol, 1.0 M in hexane) is added tocompound 2 (25 g, 113.5 mmol, dissolved in 100 ml of dried THF), andstirred for 1 hour, followed by addition of cyclopentyl bromide (25 g,168 mmol). The reaction is kept at −78° C. for 4 hours, then slowlywarmed up to room temperature and allowed to react for another 12 hours.The completion of the reaction is followed by TLC. With stirring, asolution of 10% of NH₄Cl (25 ml) is added to the mixture. Then, themixture is poured into a separation funnel containing 10% NH₄Cl solution(200 ml). The aqueous layer is discarded, and the organic layer is driedover Na₂SO₄. The solvent is removed to give a crude product, which isthen re-crystallized in hexane to give a pure product.

Step 3: Making Compound 4.

R(−)-cyclopentylmandelic acid (compound 4) is prepared by providingcompound 3 in aqueous methanolic potassium hydroxide at 65° C. for fourhours. After cooling this mixture to room temperature and removing themethanol under vacuum, the aqueous solution is acidified with aqueoushydrochloric acid. The aqueous solution is then extracted twice withethyl acetate and the organic phase dried with anhydrous sodium sulfate.After removing the solvent and performing a recrystallization, pureR(−)-cyclopentylmandelic acid (compound 4) is obtained.

Synthesis of (S)-1-methylpyrrolidin-3-ol (70)

(S)-1-methylpyrrolidin-3-ol (compound 70) was prepared starting withS(+)-malic acid.

Step 4: Making Compound 6.

S(+)-malic acid (also known as (R)-2-hydroxysuccinic acid) (compound 50)is reacted with methyl amine (CH₃NH₂) to form(S)-3-hydroxy-1-methylpyrrolidine-2,5-dione (compound 60).(S)-3-hydroxy-1-methylpyrrolidine-2,5-dione (6) is treated with areducing agent to form (S)-1-methylpyrrolidin-3-ol (compound 70). In oneinstance, reduction of compound 60 is performed using NaAlH₄/LiCl. To acooled solution of lithium chloride (0.11 mol) in THF is added NaAlH₄(0.22 mol) in toluene/THF under argon.

N-methylsuccinimide (0.083 mol) in THF is added while holding thetemperature below 15° C. After the addition is complete, the reaction isallowed to warm to room temperature. After 30 minutes at roomtemperature, the reaction is heated to greater than 40° C. for 2 hr. Thereaction is then cooled to less than 5° C. and toluene (50 ml) is thenadded. Water (9 ml) is then added slowly holding the temperature below15° C. Additional H₂O or aqueous NaOH is used as necessary. Theinsoluble inorganic salts are removed by filtration. These solids arewashed with additional THF or toluene to obtain a solution whichcontained N-methyl pyrrole, as determined by GLC analysis.

Synthesis of threo-glycopyrrolate base: 2R3′S-glycopyrrolate base (21)

Step 5: Making Compound 21.

R(−)-cyclopentylmandelic acid (4) is coupled to(S)-1-methylpyrrolidin-3-ol (70) to make the diasterically pure2R3′S-glycopyrrolate base (compound 21) using 1,1-carbonyldiimideazole(CDI) activated esterification.

Step 6: Making Compound 100.

The glycopyrrolate base, compound 21, is treated in dry acetonitrilewith methyl bromoacetate at room temperature under stirring for three(3) hours. The crude product is dissolved in a small volume of methylenechloride and poured into dry ethyl ether to obtain a precipitate. Thisprocedure is repeated three times to provide(3S)-3-((R)-2-cyclopentyl-2-hydroxy-2-phenylacetoxy)-1-(2-ethoxy-2-oxoethyl)-1-methylpyrrolidin-1-iumbromide, also known as3′(S)-[R-Cyclopentylphenylhydroxyacetoy]-1′-ethyl-1′methoxycarbonylpyrrolidiniumbromide (compound 100).

The embodiments and examples described above are intended to be merelyillustrative and non-limiting. Those skilled in the art will recognizeor will be able to ascertain using no more than routine experimentation,numerous equivalents of specific compounds, materials and procedures.All such equivalents are considered to be within the scope and areencompassed by the appended claims.

What is claimed is:
 1. A process for making a compound of Formula (I):

wherein: R¹ and R² are each, independently in each instance, selectedfrom alkyl and alkyl substituted with alkoxycarbonyl; the stereochemicalconfiguration about the carbon atom indicated by 2 is R; thestereochemical configuration about carbon atom indicated by 3′ is R; X⁻is an anion; wherein the process comprises step (1) contacting acompound of Formula (Ia) with a compound of Formula (Ib) under couplingconditions to form a compound of Formula (Ic):

and step (2) contacting a compound of Formula (Ic) with a compound ofFormula (Id) to make a compound of Formula (I):


2. The process of claim 1, further comprising: step (3) isolating astereomerically pure stereoisomer of a compound of Formula (I).
 3. Theprocess of claim 2, wherein isolating a stereomerically purestereoisomer of a compound of Formula (I) is by column chromatography orby simulated moving bed (SMB) separation.
 4. (canceled)
 5. (canceled) 6.The process of claim 1, wherein R¹ is alkyl.
 7. The process of claim 6,wherein R¹ is methyl, ethyl, n-propyl, propyl, n-butyl, t-butyl,i-butyl, n-pentyl, or i-pentyl.
 8. The process of claim 7, wherein R¹ ismethyl or ethyl.
 9. (canceled)
 10. (canceled)
 11. The process of claim1, wherein R² is alkyl.
 12. The process of claim 11, wherein R² ismethyl, ethyl, n-propyl, propyl, n-butyl, t-butyl, i-butyl, n-pentyl, ori-pentyl.
 13. The process of claim 12, wherein R² is methyl or ethyl.14. (canceled)
 15. (canceled)
 16. The process of claim 1, wherein R¹ isalkyl substituted with alkoxycarbonyl.
 17. (canceled)
 18. The process ofclaim 16, wherein R¹—CH₂C(O)OCH₂CH₃.
 19. (canceled)
 20. (canceled) 21.The process of claim 18, wherein R² is methyl.
 22. (canceled)
 23. Theprocess of claim 1, wherein in step (1), compounds of Formula (Ia) andFormula (Ib) are stereomerically pure.
 24. The process of claim 1,wherein the compound of Formula (I) has the following structure (Ia1) or(Ia2):


25. The process of claim 1, wherein the compound of Formula (I)comprises a compound having the following structure:


26. The process of claim 1, wherein the compound of Formula (I)comprises a mixture of compounds having the following structures:


27. (canceled)
 28. (canceled)
 29. The process of claim 1, wherein thecompound of Formula (I) is the following:


30. The process of claim 1, wherein the compound of Formula (I) is thefollowing:


31. The process of claim 1, wherein the compound of Formula (I) is thefollowing:


32. The process of claim 1, wherein in step (1) a compound of Formula(Ib-s) is present:


33. (canceled)
 34. (canceled)
 35. The process of claim 2, whereinisolating compound (Ic) from a mixture compound (Ic) and itsstereoisomers comprises using chiral resolution agents and salts. 36.The process of claim 1, wherein R¹ and R² are both alkyl. 37.-40.(canceled)
 41. The process of claim 1, wherein X⁻ is halide.
 42. Theprocess of claim 41, wherein X⁻ is selected from the group consisting ofF⁻, Cl⁻, Br⁻, I⁻ and combinations thereof.
 43. (canceled)
 44. (canceled)45. The process of claim 1, wherein the compound of Formula (Ib) iscompound (7):


46. The process of claim 1, wherein the compound of Formula (Ic) iscompound (8):


47. The process of claim 1, wherein the compound of Formula (I) is thefollowing compound:


48. The process of claim 1, wherein the compound of Formula (I) iscompound (9):


49. The process of claim 1, wherein the compound of Formula (Id) is thefollowing compound:


50. The process of claim 1, wherein the compound of Formula (Id) is thefollowing compound:


51. The process of claim 1, wherein the compound of Formula (IA) iscompound (4):

and wherein compound (4) is made by contacting compound (3):

with methanolic potassium hydroxide. 52.-56. (canceled)
 57. The processof claim 51, comprising crystallizing the compound (4).
 58. The processof claim 51, wherein compound (3) is made by contacting compound (2)with LiHMDS and cyclopentyl bromide:


59. (canceled)
 60. The process of claim 1, wherein the compound ofFormula (Ib) is compound (7):

and wherein compound (7) is made by contacting compound (6) with areducing agent:


61. The process of claim 60, wherein compound (6) is made by contactingR(−)-malic acid, compound (5), with methyl amine:


62. (canceled)
 63. (canceled)
 64. A process of making a compound ofFormula (Ib):

wherein R¹ is alkyl; comprising: step (3): providing a compound (5):

step (4): contacting compound (5) with methyl amine to form a compoundof Formula Ibc:

and contacting compound (Ibc) with a reducing agent to form a compoundof Formula (Ib):

65.-75. (canceled)
 76. A composition comprising a mixture of compoundshaving following structures (Ia1a) and (Ia1b):

wherein the compounds having structures (Ia1a) and (Ia1b) are preparedby the process of claim
 1. 77. A composition comprising a compoundhaving following structure:

wherein the compound is prepared by the process of claim
 1. 78.-80.(canceled)
 81. A method of treating hyperhidrosis, comprisingadministering to a subject in need thereof a composition comprising acompound prepared by the process of claim
 1. 82. A method of treating adisease or disorder marked by a need for an anticholinergic agent,comprising administering to a subject in need thereof a compositioncomprising a compound prepared by the process of claim
 1. 83.-85.(canceled)